Novel molecular targets for atrial fibrillation therapy

D Dobrev, L Carlsson, S Nattel - Nature reviews Drug discovery, 2012 - nature.com
Atrial fibrillation is the most common type of cardiac arrhythmia, and is responsible for
substantial morbidity and mortality in the general population. Current treatments have …

Ultra-rapid delayed rectifier channels: molecular basis and therapeutic implications

U Ravens, E Wettwer - Cardiovascular research, 2011 - academic.oup.com
The ultrarapid delayed rectifier channels have attracted considerable interest as targets for
'atrial-selective'antiarrhythmic drugs because they contribute to atrial but not to ventricular …

A detailed mathematical model of the human atrial cardiomyocyte: Integration of electrophysiology and cardiomechanics

F Mazhar, C Bartolucci, F Regazzoni… - The Journal of …, 2024 - Wiley Online Library
Mechano‐electric regulations (MER) play an important role in the maintenance of cardiac
performance. Mechano‐calcium and mechano‐electric feedback (MCF and MEF) pathways …

[HTML][HTML] Pathology-specific effects of the IKur/Ito/IK, ACh blocker AVE0118 on ion channels in human chronic atrial fibrillation

T Christ, E Wettwer, N Voigt, O Hala… - British journal of …, 2008 - ncbi.nlm.nih.gov
Background and purpose This study was designed to establish the pathology-specific
inhibitory effects of the I Kur/I to/IK, ACh blocker AVE0118 on atrium-selective channels and …

A specific two-pore domain potassium channel blocker defines the structure of the TASK-1 open pore

AK Streit, MF Netter, F Kempf, M Walecki… - Journal of biological …, 2011 - ASBMB
Two-pore domain potassium (K 2P) channels play a key role in setting the membrane
potential of excitable cells. Despite their role as putative targets for drugs and general …

Kv1. 5 blockers preferentially inhibit TASK-1 channels: TASK-1 as a target against atrial fibrillation and obstructive sleep apnea?

AK Kiper, S Rinné, C Rolfes, D Ramírez… - … -European Journal of …, 2015 - Springer
Atrial fibrillation and obstructive sleep apnea are responsible for significant morbidity and
mortality in the industrialized world. There is a high medical need for novel drugs against …

Molecular mechanisms underlying urate-induced enhancement of Kv1. 5 channel expression in HL-1 atrial myocytes

N Maharani, YK Ting, J Cheng, A Hasegawa… - Circulation …, 2015 - jstage.jst.go.jp
Background: Hyperuricemia induces endothelial dysfunction, oxidative stress and
inflammation, increasing cardiovascular morbidities. It also raises the incidence of atrial …

New drugs targeting the cardiac ultra-rapid delayed-rectifier current (IKur): rationale, pharmacology and evidence for potential therapeutic value

JW Ford, JT Milnes - Journal of cardiovascular pharmacology, 2008 - journals.lww.com
There is a clear unmet medical need for new pharmacologic therapies for the treatment of
atrial fibrillation (AF) with improved efficacy and safety. This article reviews the development …

Current drug treatment strategies for atrial fibrillation and TASK-1 inhibition as an emerging novel therapy option

M Kraft, A Buescher, F Wiedmann, Y L'hoste… - Frontiers in …, 2021 - frontiersin.org
Atrial fibrillation (AF) is the most common sustained arrhythmia with a prevalence of up to
4% and an upwards trend due to demographic changes. It is associated with an increase in …

Targeting the voltage-dependent K+ channels Kv1. 3 and Kv1. 5 as tumor biomarkers for cancer detection and prevention

A Felipe, J Bielanska, N Comes… - Current medicinal …, 2012 - ingentaconnect.com
Potassium channels (KCh) are a diverse group of membrane proteins that participate in the
control of the membrane potential. More than eighty different KCh genes have been …